Papillomaviruses: A correlation between immune evasion and oncogenicity?

Trends in Microbiology

Volumn 11, Issue 7, 2003, Pages 300-305

  O'Brien, Philippa M ^a,b   Campo, M Saveria ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSFORMING PROTEIN; TRANSFORMING PROTEIN E5; TRANSFORMING PROTEIN E6; TRANSFORMING PROTEIN E7; UNCLASSIFIED DRUG;

CANCER; CARCINOGENICITY; CELL TRANSFORMATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA TUMOR VIRUS; DOWN REGULATION; GAP JUNCTION; GOLGI COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION RISK; LYSOSOME; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UTERINE CERVIX TUMOR; VIRUS INFECTION;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; PAPOVAVIRIDAE;

EID: 0142043805     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(03)00145-8     Document Type: Article

References (51)

1. Breitburd F., et al. HLA control in the progression of human papillomavirus infections. Semin. Cancer Biol. 7:1996;359-371.
2. Krul E.J., et al. HLA and susceptibility to cervical neoplasia. Hum. Immunol. 60:1999;337-342.
3. Castellsague X., et al. Environmental cofactors in human papillomavirus carcinogenesis. Virus Res. 89:2002;191-199.
4. Frazer I.H., et al. Potential strategies utilized by papillomavirus to evade host immunity. Immunol. Rev. 168:1999;131-142.
5. Bosch F.X., et al. The causal relationship between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:2002;244-265.
6. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 20:2001;7874-7887.
7. Munger K., et al. Biological activities and molecular targets of the human papillomavirus oncoprotein. Oncogene. 20:2001;7888-7898.
8. Guccione E., et al. Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology. 293:2002;20-25.
9. Alloub M.I., et al. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ. 298:1989;153-156.
10. Campo M.S. Bovine papillomavirus and cancer. Vet. J. 154:1997;175-188.
11. Ozsaran A.A., et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papillomavirus infection in renal transplant patients receiving immunosuppressive therapy. Eur. J. Gynaecol. Oncol. 20:1999;127-130.
12. Harwood C.A., et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61:2000;289-297.
13. Heard I., et al. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet. Gynecol. 96:2000;403-409.
14. Jay N., Moscicki A.B. Human papillomavirus infections in women with HIV disease: prevalence, risk and management. AIDS Read. 10:2000;659-668.
15. Del Mistro A., Chieco Bianchi L. HPV-related neoplasias in HIV-infected individuals. Eur. J. Cancer. 37:2001;1227-1235.
16. Frazer I.H. Immunology of papillomavirus infection. Curr. Opin. Immunol. 8:1996;484-491.
17. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer. 2:2002;59-65.
18. O'Brien P.M., Campo M.S. Evasion of host immunity directed by PV-encoded proteins. Virus Res. 88:2002;103-117.
19. Venuti A., Campo M.S. The E5 protein of papillomaviruses. McCance D.J. Human Papillomaviruses. 2002;143-164 Elsevier Science.
20. Ashrafi G.H., et al. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene. 21:2002;248-259.
21. Marchetti B., et al. The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface. Oncogene. 21:2002;7808-7816.
22. Hildesheim A., et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169:1994;235-240.
23. Elfgren K., et al. A population-based five-year follow-up study of cervical human papillomavirus infection. Am. J. Obstet. Gynecol. 183:2000;561-567.
24. Alcami A., Koszinowski U.H. Viral mechanisms of immune evasion. Trends Microbiol. 8:2000;410-418.
25. Ronco L.V., et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:1998;2061-2072.
26. Li S., et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α Oncogene. 18:1999;5727-5737.
27. Park J.S., et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275:2000;6764-6769.
28. Barnard P., et al. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α Virology. 277:2000;411-419.
29. Georgopoulos N.T., et al. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene. 19:2000;4930-4935.
30. Arends M.J., et al. Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. Hum. Pathol. 24:1993;432-437.
31. Burger R.A., et al. Human papillomavirus type 18 association with poor prognosis in early stage cervical cancer. J. Natl. Cancer Inst. 88:1996;1361-1368.
32. Cox J.T. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus. Baillieres Clin. Obstet. Gynaecol. 9:1995;1-37.
33. Pereira D.S., et al. Identification of adenovirus E1A regions which affect MHC class I expression and susceptibility to cytotoxic T lymphocytes. Virology. 211:1995;268-277.
34. Proffitt J.A., Blair G.E. The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells. FEBS Lett. 400:1997;141-144.
35. Glew S.S., et al. HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. Eur. J. Cancer. 29A:1993;1963-1970.
36. Cromme F.V., et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br. J. Cancer. 67:1993;1372-1380.
37. Vambutas A., et al. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin. Immunol. 101:2001;94-99.
38. Giannoudis A., Herrington C.S. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 193:2001;295-302.
39. de Campos-Lima P.O., et al. T cell responses and virus evolution: loss of HLA A11-restircted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J. Exp. Med. 179:1994;1297-1305.
40. Chen W.N., Oon C.J. Mutation 'hot spot' in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 262:1999;757-761.
41. Heinzel P.A., et al. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J. Clin. Microbiol. 33:1995;1746-1754.
42. Ellis J.R., et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat. Med. 1:1995;464-470.
43. Duggan-Keen M.F., et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur. J. Immunogenet. 23:1996;275-284.
44. Crook T., et al. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 67:1991;547-556.
45. Londesborough P., et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesioins in women with minor cervical abnormalities. Int. J. Cancer. 69:1996;364-368.
46. Yamada T., et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 71:1997;2463-2472.
47. Zehbe I., et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58:1998;829-833.
48. Kast W.M., et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152:1994;3904-3912.
49. Eriksson A., et al. Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. J. Gen. Virol. 80:1999;595-600.
50. Bible J.M., et al. Cervical lesions are associated with human papillomavirus type 16 intratypic variants that have high transcriptional activity and increased usage of common mammalian codons. J. Gen. Virol. 81:2002;1517-1527.
51. +-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene. 19:2000;3727-3732.